Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.
Q2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following:
a. Belantamab Mafodotin [Blenrep]
b. Bortezomib [Velcade] monotherapy or with dexamethasone
c. Bortezomib, thalidomide and dexamethasone [VTD]
d. Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)
e. Carfilzomib [Kyprolis] and dexamethasone
f. Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone
g. Daratumumab [Darzalex] monotherapy
h. Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)
i. Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)
j. Elranatamab
k. Idecabtagene vicleucel [Abecma]
l. Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)
m. Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as IRd)
n. Lenalidomide [Revlmid] monotherapy
o. Lenalidomide [Revlimid] and dexamethasone
p. Pomalidomide [Imnovid] and dexamethasone
q. Selinexor and dexamethasone
r. Talquetamab
s. Teclistamab [Tecvayli]
t. Any other systemic anti-cancer therapy
